Alpha Crest Capital Management LLC Fate Therapeutics Inc Transaction History

Alpha Crest Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $269,795 - $462,397	12,823 New	12,823 $287,000
Q4 2021 Feb 09, 2022	SELL	$47.84 - $64.34 $341,912 - $459,837	-7,147 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$59.27 - $95.73 $518,375 - $837,254	-8,746 Reduced 55.03%	7,147 $424,000
Q2 2021 Aug 12, 2021	BUY	$67.25 - $92.52 $865,238 - $1.19 Million	12,866 Added 425.04%	15,893 $1.38 Million
Q1 2021 May 13, 2021	BUY	$72.16 - $117.4 $218,428 - $355,369	3,027 New	3,027 $250,000
Q4 2020 Feb 12, 2021	SELL	$38.09 - $100.95 $399,945 - $1.06 Million	-10,500 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$30.41 - $40.5 $319,305 - $425,250	10,500 New	10,500 $420,000
Q2 2020 Aug 12, 2020	SELL	$20.21 - $35.23 $191,186 - $333,275	-9,460 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$17.28 - $31.88 $163,468 - $301,584	9,460 New	9,460 $210,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $161M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Crest Capital Management LLC with notifications on news.